Your browser is no longer supported. Please, upgrade your browser.
Omnicell, Inc.
Index- P/E195.75 EPS (ttm)0.78 Insider Own1.70% Shs Outstand42.96M Perf Week0.80%
Market Cap6.57B Forward P/E37.93 EPS next Y4.01 Insider Trans-4.37% Shs Float42.59M Perf Month2.99%
Income35.00M PEG13.05 EPS next Q0.82 Inst Own- Short Float6.06% Perf Quarter10.43%
Sales914.40M P/S7.19 EPS this Y-48.50% Inst Trans-0.09% Short Ratio10.87 Perf Half Y26.31%
Book/sh23.53 P/B6.46 EPS next Y11.57% ROA2.10% Target Price156.67 Perf Year126.34%
Cash/sh12.92 P/C11.77 EPS next 5Y15.00% ROE3.70% 52W Range65.21 - 154.92 Perf YTD26.73%
Dividend- P/FCF33.99 EPS past 5Y-2.60% ROI2.70% 52W High-2.32% Beta1.05
Dividend %- Quick Ratio2.80 Sales past 5Y13.00% Gross Margin46.90% 52W Low132.07% ATR3.53
Employees2860 Current Ratio3.10 Sales Q/Q9.60% Oper. Margin4.70% RSI (14)58.24 Volatility2.22% 2.30%
OptionableYes Debt/Eq0.47 EPS Q/Q17.50% Profit Margin3.80% Rel Volume0.36 Prev Close152.10
ShortableYes LT Debt/Eq0.47 EarningsJul 29 BMO Payout0.00% Avg Volume237.46K Price151.33
Recom2.00 SMA200.24% SMA505.22% SMA20021.48% Volume83,445 Change-0.51%
Jun-09-21Initiated JP Morgan Neutral $146
May-24-21Initiated BTIG Research Buy $165
Feb-02-21Upgrade Piper Sandler Neutral → Overweight $86 → $147
Dec-08-20Initiated Berenberg Buy $145
Dec-03-20Downgrade Cantor Fitzgerald Overweight → Neutral $95
Jul-07-20Initiated Stephens Overweight $90
Feb-07-20Reiterated Dougherty & Company Buy $92 → $100
Nov-21-19Reiterated Dougherty & Company Buy $90 → $92
Jul-26-19Upgrade Craig Hallum Hold → Buy $85
Mar-07-19Reiterated Dougherty & Company Buy $78 → $90
Jun-29-18Resumed The Benchmark Company Buy $63
Sep-05-17Reiterated The Benchmark Company Buy $55 → $67
Jul-28-17Reiterated Dougherty & Company Buy $45 → $49
Apr-21-17Downgrade Piper Jaffray Overweight → Neutral
Jan-19-17Initiated Dougherty & Company Buy $44
Dec-06-16Reiterated The Benchmark Company Buy $39 → $55
Jul-07-16Reiterated FBR Capital Outperform $35 → $40
Mar-21-16Reiterated Topeka Capital Markets Buy $38 → $37
Jan-07-16Initiated The Benchmark Company Buy $33
Nov-16-15Reiterated Topeka Capital Markets Buy $40 → $38
Jul-22-21 03:03PM  
Jul-20-21 10:42PM  
Jul-14-21 06:20AM  
Jul-12-21 08:31AM  
Jul-09-21 07:33AM  
Jul-08-21 11:40AM  
Jul-07-21 08:00AM  
Jul-01-21 05:12AM  
Jun-25-21 08:00AM  
Jun-22-21 11:40AM  
Jun-21-21 04:29PM  
Jun-03-21 11:40AM  
May-19-21 06:20AM  
May-18-21 11:40AM  
May-02-21 03:47AM  
Apr-30-21 10:29AM  
Apr-29-21 05:35PM  
Apr-28-21 04:29AM  
Apr-27-21 08:01AM  
Apr-22-21 12:33PM  
Apr-15-21 08:00AM  
Apr-12-21 08:23AM  
Apr-08-21 07:56AM  
Apr-07-21 08:01AM  
Apr-05-21 09:37AM  
Apr-01-21 04:05PM  
Mar-29-21 06:59AM  
Mar-15-21 04:26PM  
Mar-12-21 07:37AM  
Mar-08-21 11:00AM  
Mar-03-21 11:30AM  
Mar-02-21 10:11AM  
Feb-26-21 03:35AM  
Feb-22-21 08:30AM  
Feb-12-21 04:01PM  
Feb-02-21 08:35AM  
Feb-01-21 09:00PM  
Jan-29-21 05:57AM  
Jan-28-21 10:40AM  
Jan-27-21 10:42AM  
Jan-26-21 04:01PM  
Jan-25-21 12:30PM  
Jan-22-21 12:13PM  
Jan-19-21 09:52AM  
Jan-18-21 12:45PM  
Jan-15-21 08:51AM  
Jan-13-21 08:01AM  
Jan-11-21 08:00AM  
Jan-04-21 08:00AM  
Dec-28-20 04:55AM  
Dec-21-20 04:30PM  
Dec-18-20 10:45PM  
Dec-15-20 05:02PM  
Dec-10-20 08:44AM  
Dec-09-20 11:55AM  
Dec-08-20 05:56PM  
Nov-30-20 04:11AM  
Nov-12-20 03:55PM  
Nov-11-20 08:01AM  
Nov-10-20 08:01AM  
Nov-09-20 08:01AM  
Nov-06-20 05:27PM  
Nov-03-20 09:14AM  
Oct-27-20 08:31PM  
Oct-26-20 10:18AM  
Oct-22-20 08:01AM  
Oct-20-20 12:31PM  
Oct-06-20 12:38PM  
Oct-01-20 04:01PM  
Sep-29-20 04:53PM  
Sep-23-20 11:24AM  
Sep-22-20 07:00AM  
Sep-08-20 01:13PM  
Sep-01-20 04:15PM  
Aug-27-20 11:31AM  
Aug-18-20 10:51AM  
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSTON DAN SEVP & Chief Legal & AdminJul 20Option Exercise0.0024,489059,965Jul 21 04:29 PM
JOHNSTON DAN SEVP & Chief Legal & AdminJul 20Sale151.3531,2364,727,70728,729Jul 21 04:29 PM
Kuipers Peter J.Executive V P& CFOMay 18Sale135.532,395324,59969,454May 18 05:09 PM
MELLON CHRISTINE MARIEEVP, Chief People OfficerMay 04Buy137.64435,91914,510May 05 11:16 AM
Seim Robin GeneDirectorJan 04Sale119.621,319157,77935,558Jan 04 05:18 PM
Seidelmann Scott PeterEVP, Chief Commercial OfficerDec 16Sale115.482,125245,39527,048Dec 17 04:16 PM
LIPPS RANDALL AChairman, President and CEODec 09Option Exercise0.0025,0000177,116Dec 09 05:23 PM
LIPPS RANDALL AChairman, President and CEODec 09Sale121.8525,0003,046,241152,116Dec 09 05:23 PM
LIPPS RANDALL AChairman, President and CEODec 08Option Exercise0.0017,5000168,965Dec 08 04:53 PM
LIPPS RANDALL AChairman, President and CEODec 08Sale110.5617,5001,934,718152,116Dec 08 04:53 PM
LIPPS RANDALL AChairman, President and CEONov 23Option Exercise0.0012,6000164,716Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 23Sale105.4012,6001,328,030152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Option Exercise0.002,4000154,516Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 20Sale105.012,400252,034152,116Nov 23 06:24 PM
LIPPS RANDALL AChairman, President and CEONov 04Sale89.5911,4351,024,439229,113Nov 04 05:48 PM
LIPPS RANDALL AChairman, President and CEOSep 16Sale75.6413,7431,039,501240,548Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOSep 15Sale75.011,400105,009254,291Sep 16 07:56 PM
LIPPS RANDALL AChairman, President and CEOJul 29Sale75.153,718279,398148,398Jul 30 12:42 PM